<DOC>
	<DOCNO>NCT02789813</DOCNO>
	<brief_summary>The purpose study evaluate whether valproic acid combination fear memory reactivation useful enhance treatment stability exposure therapy specific phobia .</brief_summary>
	<brief_title>Influence Valproic Acid Extinction-based Therapy Patients With Fear Spiders .</brief_title>
	<detailed_description>- There one screening visit ( visit 1 ) , one intervention visit ( visit 2 ) one follow-up visit ( 90 day visit 2 ) ( visit 3 ) . - On visit 2 participant undergo 30 min exposure therapy virtual reality pre-defined spider situation . - Duration individual participant 15 week depend time pass screening ( visit 1 ) intervention visit ( visit 2 ) . - Change phobic fear baseline ( visit 1 ) assess 90 day follow-up ( visit 3 ) . - Documentation study relevant source data every study participant do complete study specific electronic case report form ( eCRF , SoSci Survey ) study specific case report form paper ( Adverse Events , Serious Adverse Events concomitant medication ) . Data eCRF validate completeness discrepancy automatically . An audit trail system maintain record initial entry change ( reason change , time date change , user identification entry change ) . - Quality insurance do external site monitoring ( include study progress , accuracy completeness eCRF , fulfillment protocol requirement , applicable local authority regulation investigator 's obligation ) . - Monitoring include 100 % safety parameter , primary endpoint , inform consent document Trial Master File Initiation Visit Close Out . - Standard Operating Procedures address study activity patient recruitment , informed consent , study intervention , data collection , data management , data analysis , report adverse event exist .</detailed_description>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>DSMIV diagnosis specific phobia ( animal type : spider ) BAT score ( screen ) 1 7 point Physically healthy Normotensive ( 90/60140/90 mmHg ) Male female Aged 18 40 year Native fluent Germanspeaking Females effective birth control Other axis I disorder except comorbid phobic disorder Concurrent psychotherapy pharmacotherapy Previous exposurebased therapy specific phobia Parallel participation another study Body weight less 50kg Longterm medication intake Substance abuse 5 cigarette day and/or inability abstinent least 5 hour Pregnancy breastfeed Kinetosis History coagulation disease History gastrointestinal disease Laboratory exclusion criterion : clinically relevant deviation laboratory value ( blood count , blood chemistry , coagulation status , liver pancreas enzyme , electrolyte ) normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>